| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Unité 219 INSERM, Institut Curie-Biologie, Labs. 110112, Centre Universitaire, 91405 Orsay Cedex, France
The cytotoxic effect of the 9-azaellipticine derivative pazelliptine in combination with
-ray irradiation was investigated using Chinese hamster V-79 cells in culture.
-ray irradiation and drug treatment (1-h drug exposure) were applied at 1-h intervals for partial DNA damage recovery in growth medium. Isobologram analysis of the clonogenic potential gave evidence of supraadditive interaction in the radiation
drug sequence with 10% survival as an endpoint. No synergistic potentiation was observed at higher survival or as pazelliptine was applied first. Pazelliptine abolished the low-dose shoulder characteristic of asynchronous cell response to
-rays. Although rejoining of radiation-induced DNA strand breaks was completed at the time of drug exposure, pazelliptine brought about a larger amount of DNA strand breaks in preirradiated than in nonirradiated cells.
The time and dose dependencies of DNA strand break formation and repair with radiation and/or pazelliptine were analyzed by neutral and alkaline filter elution. Pazelliptine in the micromolar range showed the same pattern of double-stranded cleavable complex formation as expected of a DNA topoisomerase II-targeting agent. At a low concentration of pazelliptine, however, protein-concealed breaks were mostly in the form of single-stranded adducts. Such single-stranded complexes have been reported to occur with some topoisomerase II-targeting drugs; their properties are also reminiscent of those induced by the topoisomerase I poison, camptothecin. It is proposed that topoisomerase poisoning interacts with the repair of radiation-induced lesions.
1 This work was supported by a research fellowship from the Centre Hospitalier Universitaire de Montpellier to J. B., by financial aid from the Institut National de la Santé et de la Recherche Médicale, and by a grant (No. 89-21-5) from the Institut Curie.
2 Present address: Service de Radiothérapie, Hôpital Tenon, 4 Rue de la Chine, 75970 Paris Cedex 20, France.
3 To whom requests for reprints should be addressed.
Received 11/21/90. Accepted 4/ 2/91.
This article has been cited by other articles:
![]() |
C. Godon, F. P. Cordelieres, D. Biard, N. Giocanti, F. Megnin-Chanet, J. Hall, and V. Favaudon PARP inhibition versus PARP-1 silencing: different outcomes in terms of single-strand break repair and radiation susceptibility Nucleic Acids Res., August 1, 2008; 36(13): 4454 - 4464. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Noel, C. Godon, M. Fernet, N. Giocanti, F. Megnin-Chanet, and V. Favaudon Radiosensitization by the poly(ADP-ribose) polymerase inhibitor 4-amino-1,8-naphthalimide is specific of the S phase of the cell cycle and involves arrest of DNA synthesis. Mol. Cancer Ther., March 1, 2006; 5(3): 564 - 574. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Reis, N. Giocanti, C. Hennequin, F. Megnin-Chanet, M. Fernet, R. Filomenko, A. Bettaieb, E. Solary, and V. Favaudon A role for PKC{zeta} in potentiation of the topoisomerase II activity and etoposide cytotoxicity by wortmannin Mol. Cancer Ther., October 1, 2005; 4(10): 1457 - 1464. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. MIYAMOTO, T. T. HUANG, S. WUERZBERGER-DAVIS, W. G. BORNMANN, J. J. PINK, C. TAGLIARINO, T. J. KINSELLA, and D. A. BOOTHMAN Cellular and Molecular Responses to Topoisomerase I Poisons: Exploiting Synergy for Improved Radiotherapy Ann. N.Y. Acad. Sci., December 1, 2000; 922(1): 274 - 292. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |